MaxCyte Introduces the 2014 MaxCyte STX Scalable Transfection System for Cell-based Assay Applications at the SLAS 2014 Annual Conference & Exhibition

Scientists from the Novartis Institutes for Biomedical Research and AstraZeneca present case studies on the broad applicability of the MaxCyte STX for Cell-based Screening

GAITHERSBURG, Md.--()--MaxCyte®, Inc., the pioneer in scalable, high-performance cell transfection systems, will be leading a series of events at the SLAS 2014 Annual Conference and Exhibition to be held at the San Diego Convention Center, January 18-22. Throughout the conference, MaxCyte scientists will be available in Booth #846 for one-on-one technical discussions and to demonstrate the operation of the newly released 2014 MaxCyte STX® Scalable Transfection System, a smaller footprint version of the original instrument with the same high transfection performance and capacity. In a scientific tutorial sponsored by MaxCyte at 12:30PM on Tuesday, scientists from the Novartis Institute of Biomedical Research and AstraZeneca will present case studies demonstrating the use of the MaxCyte STX in the rapid development of cell-based assays for screening ion channels, GPCR, and other targets.

Dr. James Brady, Director of Technical Applications at MaxCyte, will moderate a tutorial entitled “Acceleration of Cell-based Screening Using Scalable Transient Transfection: Expression of Receptor & Enzyme Targets in Relevant Cell Types”. Martin Henault of Novartis Institutes for Biomedical Research and Dr. Helena Peilot, PhD, of AstraZeneca will each present case studies using MaxCyte’s unique transient transfection technology in cell-based screening for pharmaceutical development. Topics covered in the tutorial will include the speed of assay development, transfection of complex targets, and use of biologically relevant cells.

“The work at the Novartis Institutes for Biomedical Research and at AstraZeneca demonstrates the universality of the MaxCyte STX Scalable Transfection System for different targets, assay formats, and cell types used in cell-based assays,” says Dr. Karen Donato, Executive Vice President of Global Business Development and Marketing at MaxCyte. “The MaxCyte STX is the ideal tool for the rapid development and conduct of more predictive cell-based assays to identify high-quality drug candidates.”

“In today’s competitive environment, pharmaceutical companies need tools that will help them reliably advance and accelerate drug discovery,” says Douglas Doerfler, President and CEO of MaxCyte. “Leading researchers, such as those at Novartis and AstraZeneca, have shown how the MaxCyte Scalable Transfection System has a major impact in advancing drug discovery.”

About MaxCyte

MaxCyte specializes in cell modification technologies to enable the discovery, development, manufacturing, and delivery of innovative therapeutic products. Drawing on its cell therapy expertise, MaxCyte designed a portfolio of products including the MaxCyte STX® Scalable Transfection System and MaxCyte VLX® Large Scale Transfection System, ideal tools for use in drug discovery research and screening and protein production environments. These products provide for the rapid development and consistent production of billions of (co)transfected primary cells, stem cells, and cell lines for protein and antibody production, for rapid response vaccine development, and for cell-based assays with comparable results and Seamless Scalability™ from the bench to HTS and pilot and production scale.

For more information visit http://www.maxcyte.com.

Contacts

MaxCyte, Inc.
Meg Duskin
Marketing Communications Manager
301-944-1645
mduskin@maxcyte.com

Sharing

Contacts

MaxCyte, Inc.
Meg Duskin
Marketing Communications Manager
301-944-1645
mduskin@maxcyte.com